Published summary: 2026-03-07
Where the evidence converges
Meta-analysis of 11 RCTs finding selective cannabinoids provide a small but significant reduction in neuropathic pain (-0
Strong evidence · 42 studies
High heterogeneity across studies. The effect size is small and may not be clinically meaningful for all patients. Studies varied in cannabinoid type, dose, and neuropathic pain etiology. The search e
Meta-analysis of 550 patients found CBD reduced seizures by ~20 percentage points in severe childhood epilepsies
Strong evidence · 42 studies
Only four trials available, all in LGS and DS specifically. Results may not generalize to other epilepsy types. All trials used pharmaceutical-grade CBD (Epidiolex), so findings do not apply to unregu
A Lancet meta-analysis of 83 studies found scarce evidence that cannabinoids help depression, anxiety, PTSD, or other mental disorders, with THC products doubling adverse event rates versus placebo
Strong evidence · 42 studies
Most included RCTs examined THC-based pharmaceuticals, not CBD or whole-plant cannabis. Many conditions had very few RCTs (Tourette: 2 RCTs n=36; PTSD: 1 RCT n=10; ADHD: 1 RCT n=30). The evidence was
Where questions remain
CBD at approximately 700 mg/day for six weeks showed no significant benefit for Huntington's Disease symptoms in 15 patients, but was well tolerated with no toxicity
Moderate evidence · 139 studies
Fifteen patients is a small sample. Six weeks may be too short to detect slowly developing benefits. The crossover design assumes no carryover effects. Plasma CBD levels were relatively low despite hi
A review by THC discoverer Raphael Mechoulam tracing cannabinoids from ancient use to modern clinical applications in nausea, appetite, multiple sclerosis, arthritis, and neuroprotection
Moderate evidence · 139 studies
As a broad overview by a single researcher, this paper provided perspective rather than systematic analysis. The review covered many therapeutic areas briefly rather than deeply. Some of the promising
Randomized trial in 16 MS patients found neither oral THC nor cannabis extract reduced spasticity, and both worsened patients' overall impression compared to placebo
Moderate evidence · 139 studies
The sample of 16 patients was small and may have been underpowered to detect modest benefits. Only patients with severe spasticity were included, which may represent a population less responsive to ca
GW Pharmaceuticals developed Sativex and other cannabis medicines, with phase III trials showing significant neuropathic pain reduction in MS, leading to licensing with Bayer AG
Moderate evidence · 139 studies
This was an industry-produced review that presented the company's development program in favorable terms. Detailed trial data and methodology were not provided. The review was written before most tria
Research gaps
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Cannabis Use Makes Quitting Tobacco Harder, But CBD Might Help
With 18-22% of tobacco users also using cannabis, understanding how co-use affects quit attempts is critical. The key distinction here is that casual cannabis use hurts cessation, but pharmacologically targeted CBD could actually help.
Nearly 29% of North Americans have tried CBD, about double the rate in Europe
Despite the explosive growth of the CBD market, no prior systematic assessment of how many people actually use CBD existed. These numbers provide a baseline for tracking trends as regulations and products evolve.
Meta-Analysis Found CBD and THC Had Trivial Effects on Blood Inflammation Markers
CBD and THC are widely marketed as anti-inflammatory, often based on preclinical data. This meta-analysis of actual human clinical trials shows that the anti-inflammatory effects observed in cells and animals have not consistently translated to measurable changes in human blood markers.
Major meta-analysis of 152 RCTs finds cannabinoid effectiveness varies dramatically by specific drug and condition
By analyzing cannabinoid medications separately rather than lumping them together, this study reveals that the question "does cannabis work?" is misleading. The answer depends entirely on which cannabinoid and which condition.
Meta-analysis confirmed CBD reduces seizures by 33% in treatment-resistant epilepsy
This meta-analysis provides the strongest quantitative evidence to date supporting CBD as an add-on treatment for three of the most difficult-to-treat pediatric epilepsy syndromes.
CBD reduced seizures in both Dravet and Lennox-Gastaut syndromes, with enhanced effects when combined with clobazam
This meta-analysis directly addresses the critical question of whether CBD's seizure reduction is partly driven by its interaction with clobazam, showing CBD is effective in both clobazam users and the overall population, but more so in the combination.
How the research developed
Pre-2000
4 studies published. Includes 1 RCTs.
2000–2009
52 studies published. Includes 17 RCTs, 4 strong-evidence studies.
2010–2014
74 studies published. Includes 19 RCTs, 10 strong-evidence studies.
2015–2019
190 studies published. Includes 4 meta-analyses, 23 RCTs, 31 strong-evidence studies.
2020–present
817 studies published. Includes 19 meta-analyses, 100 RCTs, 71 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 1137 peer-reviewed studies: 23 meta-analyses (2%), 160 randomized controlled trials (14%), 122 observational studies (11%), 334 reviews (29%), 30 case studies (3%), 468 other study types (41%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.